IP Library Granted Patent US 10,156,579
Granted Patent B2
US 10,156,579 · App. 15/054,510 · Granted Dec 18, 2018

Methods for the detection of analytes in small-volume blood samples

Inventors: Ian Gibbons; Shaunak Roy (Palo Alto, CA); Edmond Ku (Palo Alto, CA)
Assignee: Theranos IP Company, LLC
G01N33/92B01L3/502707B01L3/502715B01L3/502753C12Q1/60G01N21/27G01N21/31G01N33/525G01N33/5302B01L2200/0605B01L2200/0631B01L2200/10B01L2300/0654B01L2300/087B01L2300/0819B01L2300/0874B01L2300/0887B01L2300/168G01N2201/061G01N2201/062Y10T436/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,156,579
App. No.
15/054,510
Granted
Dec 18, 2018
Kind
B2
Abstract

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

Claims (25)

1. A method of detecting an analyte in a small-volume blood sample obtained from a subject, comprising:

a) obtaining a sample of blood from a subject by lancing or pipetting, said blood sample having a volume of less than about 500 μL;

b) pre-treating the blood sample by one or more of diluting, mixing, drying, evaporating, centrifuging, and extracting;

c) introducing the blood sample into a fluidic device comprising a sample collection unit and an assay assembly, said assay assembly comprising reactants that are capable of reacting with said analyte;

d) allowing the blood sample to react with said reactants contained within said assay assembly to yield a colored product having an absorbance spectrum corresponding to at least one wavelength from a light source located within said fluidic device;

e) transmitting the at least one wavelength to the fluidic device from said light source, wherein said light source comprises a luminescent paint; and

f) detecting a change in absorption of light of the at least one wavelength transmitted to the fluidic device, wherein said change in absorption is indicative of the presence of the analyte in the blood sample.

2. The method of claim 1 , wherein the amount of absorption is related to the analyte concentration in the blood sample.

3. The method of claim 1 , wherein the amount of absorption is stoichiometrically related to the analyte concentration in the blood sample.

4. The method of claim 1 , wherein the light source further comprises a light emitting diode.

5. The method of claim 1 , wherein said luminescent paint is coated in said assay assembly.

6. The method of claim 1 , wherein the analyte is selected from the group consisting of drugs, drug metabolites, biomarkers indicative of a disease, tissue specific markers, and tissue specific enzymes.

7. The method of claim 1 , wherein the analyte is selected from the group consisting of HDL cholesterol, LDL cholesterol, total cholesterol, lipids, glucose, and enzymes.

8. The method of claim 1 , wherein the wavelength is in a range of about 400 to about 800 nm.

9. The method of claim 1 , wherein said fluidic device detects a plurality of analytes and said fluidic device comprises reactants for said plurality of analytes.

10. The method of claim 1 , wherein said assay assembly is configured to i) run an enzymatic assay yielding a colored product, or ii) run an immunoassay, or iii) both i) and ii).

11. The method of claim 1 , wherein the reactants are selected from the group of enzymes, enzyme substrates, and combinations thereof.

12. The method of claim 1 , wherein said sample of bodily fluid is less than about 50 ul.

13. The method of claim 1 , further comprising the step of quantifying the amount of said analyte present in said bodily fluid after said detecting step.

14. The method of claim 1 , wherein said introducing comprises metering a predetermined portion of said sample to be assayed in said sample collection unit, wherein said predetermined portion of the sample consists of a portion of the sample having a volume determined by the dimensions of an element of said sample collection unit.

15. The method of claim 14 , further comprising diluting and mixing said predetermined portion of said sample with a diluent in said fluidic device after the metering step to yield a diluted sample.

16. The method of claim 15 , wherein said predetermined portion of said sample is less than 50 ul.

17. The method of claim 15 , wherein said predetermined portion of said sample is less than 20 ul.

18. The method of claim 15 , wherein said predetermined portion of said sample is about 10 ul.

19. The method of claim 15 , further comprising filtering said diluted sample before allowing said diluted sample to react with said reactants.

Assignments (5)
CHANGE OF NAME Recorded Apr 7, 2020
From: THERANOS IP COMPANY LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052329/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045101/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2016
From: GIBBONS, IAN; ROY, SHAUNAK; KU, EDMOND
To: THERANOS, INC.
Reel/Frame 037838/0585 →
Continuity (5)
Continuation 14285562 · May 22, 2014
Division 12750518 · Mar 30, 2010
Continuation 11939509 · Nov 13, 2007
Provisional Application 60865805 · Nov 14, 2006
Related Publication 20160252535A1 · Sep 1, 2016